Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-45 (Canceled)

46. (Currently Amended) A pharmaceutical composition consisting essentially of a phosvitin or a phosvitin fragment of at least 20 amino acids including at least one phosphorylatable amino acid thereof which is at least [[10%]]70% dephosphorylated and a pharmaceutically-acceptable carrier, wherein the pharmaceutical composition is not an aqueous solution or a lyophilized material.

47-48 (Canceled)

49. (Previously presented) The composition of Claim 46 wherein the phosvitin is chicken phosvitin.

50.-52. (Canceled)

53. (Currently Amended) The composition of Claim 52Claim 46 wherein the phosvitin or fragment thereof is at least about 90% dephosphorylated.

54-80 (Canceled)

- 81. (Currently Amended) A kit for contacting a cell, a tissue or an organ that has been removed from an animal, the kit comprising:
- (a) a container holding a phosvitin or fragment of at least 20 amino acids including at least one phosphorylatable amino acid thereof-which is at least 70% dephosphorylated; and
- (b) instructions describing how to use the kit to contact a cell, tissue or organ with the phosvitin or fragment thereof in the kit.

82-185 (Canceled)

186. (Currently Amended) A pharmaceutical composition which is formulated for topical administration to an animal and which is not an aqueous solution, the composition consisting essentially of a phosvitin or a phosvitin fragment of at least 20 amino acids including at least one phosphorylatable amino acid thereof which is at least [[10%]]70% dephosphorylated and a pharmaceutically-acceptable carrier.

187-193 (Canceled)

Appl. No. 10/723,247 Amdt. dated February 3, 2011 Reply to Office Action mailed August 3, 2010

194. (Previously presented) The composition of Claim 186 wherein the phosvitin is chicken phosvitin.

195.-198. (Canceled)

199. (Currently Amended) The composition of <u>Claim 198Claim 186</u> wherein the phosvitin or fragment thereof is at least about 90% dephosphorylated.

200-216 (Canceled)

- 217. (Currently Amended) The pharmaceutical composition of any one of Claims 186, 195 199 or 288 199 or 288 which is formulated for topical administration to the skin of an animal.
- 218. (Currently Amended) The pharmaceutical composition of any one of Claims <u>46</u>, 186, <u>195 199 or 288199 or 288</u> which is drops, a spray, an aerosol or an inhalant.
- 219. (Currently Amended) The pharmaceutical composition of any one of Claims <u>46</u>, 186, 195-199 or 288 199 or 288 which is a powder or a foam.
- 220. (Currently Amended) The pharmaceutical composition of any one of Claims <u>46</u>, 186, 195 199 or 288199 or 288 which is a lotion, a gel, a cream, an ointment or a paste.

221-245 (Canceled)

246. (Previously presented) The pharmaceutical composition of Claim 220 which is an ointment or a cream.

247-271 (Canceled)

- 272. (Currently Amended) A pharmaceutical composition comprising a phosvitin or <u>a</u> phosvitin fragment of at least 20 amino acids including at least one phosphorylatable amino acid thereof which is at least 10% dephosphorylated and has a targeting molecule covalently attached to it and a pharmaceutically-acceptable carrier.
- 273. (Previously presented) The composition of Claim 272 wherein the composition is formulated for topical administration to an animal.

274-279 (Canceled)

280. (Canceled)

281. (Previously presented) The composition of Claim 53 wherein the phosvitin or fragment thereof is unphosphorylated.

282.-285 (Canceled)

- 286. (Currently Amended) The composition of Claim 285 Claim 49 wherein the phosvitin or fragment thereof is at least about 90% dephosphorylated.
- 287. (Previously presented) The composition of Claim 286 wherein the phosvitin or fragment thereof is unphosphorylated.
- 288. (Previously presented) The composition of Claim 199 wherein the phosvitin or fragment thereof is unphosphorylated.
 - 289.-292 (Canceled)
- 293. (Currently Amended) The composition of Claim 292Claim 194 wherein the phosvitin or fragment thereof is at least about 90% dephosphorylated.
- 294. (Previously Presented) The composition of Claim 293 wherein the phosvitin or fragment thereof is unphosphorylated.
- 295. (Currently Amended) The pharmaceutical composition of any one of Claims 194 or 289-294293-294 which is formulated for topical administration to the skin of an animal.
- 296. (Currently Amended) The pharmaceutical composition of any one of Claims 194 or 289 294293-294 which is drops, a spray, an aerosol or an inhalant.
- 297. (Currently Amended) The pharmaceutical composition of any one of Claims 194 or 289-294293-294 which is a powder or a foam.
- 298. (Currently Amended) The pharmaceutical composition of any one of Claims 194 or 289 294293-294 which is a lotion, a gel, a cream, an ointment or a paste.
- 299. (Previously Presented) The pharmaceutical composition of Claim 298 which is an ointment or a cream.